leuprolide acetate 45 MG per 0.375 ML Prefilled Syringe
- RxCUI
- 752884
- RxNorm name
- leuprolide acetate 45 MG per 0.375 ML Prefilled Syringe
- Display name
- leuprolide acetate 45 MG per 0.375 ML Prefilled Syringe
- Full name
- leuprolide acetate 45 MG per 0.375 ML Prefilled Syringe
- Term type
- SY
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:17
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Vabrinty | LEUPROLIDE ACETATE | URONOVA PHARMACEUTICALS, INC. | 008776cc-83f1-4f8c-819b-6471425da15f | 2026-04-30 | Warnings, Adverse reactions | 752884 |
| Eligard | LEUPROLIDE ACETATE | TOLMAR Inc. | b7b679a9-6823-4ef8-8d31-3ab5058ffcfc | 2026-04-30 | Warnings, Adverse reactions | 752884 |
| Fensolvi | LEUPROLIDE ACETATE | TOLMAR Inc. | 2c311700-edf4-4f2a-a468-9875489a6cc7 | 2025-09-25 | Warnings, Adverse reactions | 752884 |
| Fensolvi | LEUPROLIDE ACETATE | TOLMAR Inc. | dfb6e01c-f138-471d-bf5b-2be38247e3f0 | 2022-04-28 | Warnings, Adverse reactions | 752884 |
| ELIGARD | LEUPROLIDE ACETATE | TOLMAR Inc. | b78d1919-9dee-44fa-90f9-e0a26d32481d | 2019-04-29 | Warnings, Adverse reactions | 752884 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| b78d1919-9dee-44fa-90f9-e0a26d32481d | 0.375 ML leuprolide acetate 120 MG/ML Prefilled Syringe | SCD | 51 | These highlights do not include all the information needed to use ELIGARD ® safely and effectively. See full prescribing information for ELIGARD ® . ELIGARD ® (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002 | 20190429 |
| b78d1919-9dee-44fa-90f9-e0a26d32481d | leuprolide acetate 45 MG in 0.375 ML (6 month) Prefilled Syringe | PSN | 51 | These highlights do not include all the information needed to use ELIGARD ® safely and effectively. See full prescribing information for ELIGARD ® . ELIGARD ® (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002 | 20190429 |
| b78d1919-9dee-44fa-90f9-e0a26d32481d | leuprolide acetate 45 MG per 0.375 ML (6 month) Prefilled Syringe | SY | 51 | These highlights do not include all the information needed to use ELIGARD ® safely and effectively. See full prescribing information for ELIGARD ® . ELIGARD ® (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002 | 20190429 |
| b78d1919-9dee-44fa-90f9-e0a26d32481d | leuprolide acetate 45 MG per 0.375 ML Prefilled Syringe | SY | 51 | These highlights do not include all the information needed to use ELIGARD ® safely and effectively. See full prescribing information for ELIGARD ® . ELIGARD ® (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002 | 20190429 |
| b7b679a9-6823-4ef8-8d31-3ab5058ffcfc | 0.375 ML leuprolide acetate 120 MG/ML Prefilled Syringe | SCD | 19 | These highlights do not include all the information needed to use ELIGARD ® safely and effectively. See full prescribing information for ELIGARD. ELIGARD (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002 | 20260430 |
| b7b679a9-6823-4ef8-8d31-3ab5058ffcfc | leuprolide acetate 45 MG in 0.375 ML (6 month) Prefilled Syringe | PSN | 19 | These highlights do not include all the information needed to use ELIGARD ® safely and effectively. See full prescribing information for ELIGARD. ELIGARD (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002 | 20260430 |
| b7b679a9-6823-4ef8-8d31-3ab5058ffcfc | leuprolide acetate 45 MG per 0.375 ML Prefilled Syringe | SY | 19 | These highlights do not include all the information needed to use ELIGARD ® safely and effectively. See full prescribing information for ELIGARD. ELIGARD (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002 | 20260430 |
| b7b679a9-6823-4ef8-8d31-3ab5058ffcfc | leuprolide acetate 45 MG per 0.375 ML (6 month) Prefilled Syringe | SY | 19 | These highlights do not include all the information needed to use ELIGARD ® safely and effectively. See full prescribing information for ELIGARD. ELIGARD (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002 | 20260430 |
| dfb6e01c-f138-471d-bf5b-2be38247e3f0 | leuprolide acetate 45 MG per 0.375 ML Prefilled Syringe | SY | 17 | These highlights do not include all the information needed to use FENSOLVI ® safely and effectively. See full prescribing information for FENSOLVI. FENSOLVI (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 1985 | 20220428 |
| dfb6e01c-f138-471d-bf5b-2be38247e3f0 | 0.375 ML leuprolide acetate 120 MG/ML Prefilled Syringe | SCD | 17 | These highlights do not include all the information needed to use FENSOLVI ® safely and effectively. See full prescribing information for FENSOLVI. FENSOLVI (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 1985 | 20220428 |
| dfb6e01c-f138-471d-bf5b-2be38247e3f0 | leuprolide acetate 45 MG in 0.375 ML (6 month) Prefilled Syringe | PSN | 17 | These highlights do not include all the information needed to use FENSOLVI ® safely and effectively. See full prescribing information for FENSOLVI. FENSOLVI (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 1985 | 20220428 |
| dfb6e01c-f138-471d-bf5b-2be38247e3f0 | leuprolide acetate 45 MG per 0.375 ML (6 month) Prefilled Syringe | SY | 17 | These highlights do not include all the information needed to use FENSOLVI ® safely and effectively. See full prescribing information for FENSOLVI. FENSOLVI (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 1985 | 20220428 |
| 2c311700-edf4-4f2a-a468-9875489a6cc7 | 0.375 ML leuprolide acetate 120 MG/ML Prefilled Syringe | SCD | 12 | These highlights do not include all the information needed to use FENSOLVI ® safely and effectively. See full prescribing information for FENSOLVI. FENSOLVI (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 1985 | 20250925 |
| 2c311700-edf4-4f2a-a468-9875489a6cc7 | leuprolide acetate 45 MG per 0.375 ML (6 month) Prefilled Syringe | SY | 12 | These highlights do not include all the information needed to use FENSOLVI ® safely and effectively. See full prescribing information for FENSOLVI. FENSOLVI (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 1985 | 20250925 |
| 2c311700-edf4-4f2a-a468-9875489a6cc7 | leuprolide acetate 45 MG per 0.375 ML Prefilled Syringe | SY | 12 | These highlights do not include all the information needed to use FENSOLVI ® safely and effectively. See full prescribing information for FENSOLVI. FENSOLVI (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 1985 | 20250925 |
| 2c311700-edf4-4f2a-a468-9875489a6cc7 | leuprolide acetate 45 MG in 0.375 ML (6 month) Prefilled Syringe | PSN | 12 | These highlights do not include all the information needed to use FENSOLVI ® safely and effectively. See full prescribing information for FENSOLVI. FENSOLVI (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 1985 | 20250925 |
| 008776cc-83f1-4f8c-819b-6471425da15f | 0.375 ML leuprolide acetate 120 MG/ML Prefilled Syringe | SCD | 9 | These highlights do not include all the information needed to use VABRINTY™ safely and effectively. See full prescribing information for VABRINTY. VABRINTY (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002 | 20250601 |
| 008776cc-83f1-4f8c-819b-6471425da15f | leuprolide acetate 45 MG in 0.375 ML (6 month) Prefilled Syringe | PSN | 9 | These highlights do not include all the information needed to use VABRINTY™ safely and effectively. See full prescribing information for VABRINTY. VABRINTY (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002 | 20250601 |
| 008776cc-83f1-4f8c-819b-6471425da15f | leuprolide acetate 45 MG per 0.375 ML (6 month) Prefilled Syringe | SY | 9 | These highlights do not include all the information needed to use VABRINTY™ safely and effectively. See full prescribing information for VABRINTY. VABRINTY (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002 | 20250601 |
| 008776cc-83f1-4f8c-819b-6471425da15f | leuprolide acetate 45 MG per 0.375 ML Prefilled Syringe | SY | 9 | These highlights do not include all the information needed to use VABRINTY™ safely and effectively. See full prescribing information for VABRINTY. VABRINTY (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002 | 20250601 |